SARS-CoV-2 Clearance from Andrographis paniculata, Boesenbergia rotunda, and Favipiravir among Mild COVID-19 Cases in Klong Prem Central Prison during Mid-2021: a Retrospective Study
DOI:
https://doi.org/10.59096/osir.v15i4.262277Keywords:
Andrographis paniculata, Boesenbergia rotunda, favipiravir, mild COVID-19Abstract
This study aims to assess the effectiveness of two herbal medicines, Andrographis paniculata (Burm.f.) Nees capsule (AP) and Boesenbergia rotunda (Linn.) Mansf. extract capsule (BR), on the rate of SARS-CoV-2 virus clearance among inmates of Klong Prem Central Prison, Bangkok. Cases with mild COVID-19 were allocated into four groups: four capsules of AP thrice daily (n=30), one capsule of BR once daily (n=30), a combination of AP and BR (AP-BR) (n=30), or favipiravir (n=30) for five days. The primary outcome was time until undetected SARS-CoV-2 infection after starting treatment. The median period of SARS-CoV-2 clearance was shorter in the AP and AP-BR groups (9 days) compared to the BR (11 days) and favipiravir (13 days) groups. No one developed pneumonia; however, one participant in the AP group developed hyperkalemia. Our results suggest that A. paniculata with or without B. rotunda may be used as an alternative treatment for mild COVID-19 when access to favipiravir is limited. Further clinical trials are needed to determine their efficacy and safety
References
Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real-world effectiveness and optimal dosage of favipiravir for treatment of COVID-19: results from a multicenter observational study in Thailand. Antibiotics (Basel). 2022 Jun 15;11(6):805. doi: 10.3390/antibiotics11060805.
Sa-ngiamsuntorn K, Suksatu A, Pewkliang Y, Thongsri P, Kanjanasirirat P, Manopwisedjaroen S, et al. Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives. J Nat Prod. 2021;84(4):1261-1270.
Wanaratna K, Leethong P, Inchai N, Chueawiang W, Sriraksa P, Tabmee A, et al. Efficacy and safety of Andrographis paniculata extract in participants with mild COVID-19: a randomized controlled trial. Arch Intern Med Res. 2022;5(3):423–7. doi: 10.26502/aimr.0125.
Tanwettiyanont J, Piriyachananusorn N, Sangsoi L, Boonsong B, Sunpapoa C, Tanamatayarat P, et al. Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised participants with mild coronavirus disease 2019: a retrospective cohort study. Front Med (Lausanne). 2022 Aug 10;9:947373. doi: 10.3389/fmed.2022.947373.
Department of Medical Services, Ministry of Public Health. Guidelines for diagnosis, treatment and prevention of infection in hospital the case of coronavirus disease 2019 (COVID-19) [Internet]. Nonthaburi: Department of Medical Services; [updated 2022 Sep 29; cited 2022 Oct 24]. 16 p. <https://www.lpnh.go.th/files/drug-data/516142304.pdf>. Thai.
Kanjanasirirat P, Suksatu A, Manopwisedjaroen S, Munyoo B, Tuchinda P, Jearawuttanakul K, et al. High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci Rep. 2020 Nov 17;10(1):19963. doi: 10.1038/s41598-020-77003-3.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192–7. doi: 10.1016/S1473-3099(20)30483-7.
Zhang XY, Lv L, Zhou YL, Xie LD, Xu Q, Zou XF, Ding Y, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial. Phytother Res. 2021 Aug;35(8):4401–10. doi: 10.1002/ptr.7141.
Shu HM, He S, Sun Y, Lin CQ, Lu YF, Wu T, et al. Factors influencing viral clearance in mild COVID-19 and clinical characteristics of asymptomatic participants. Biomed Res Int. 2021 Feb 26;2021:5909612. doi: 10.1155/2021/5909612.
Ucan A, Cerci P, Efe S, Akgun H, Ozmen A, Bilgin M, et al. Benefits of treatment with favipiravir in hospitalized participants for COVID-19: a retrospective observational case–control study. Virol J. 2021 May 25;18(1):102. doi: 10.1186/s12985-021-01577-1.
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501–8. doi: 10.1016/j.ijid.2020.10.069.
Numthavaj P. Andrographis paniculata vs Boesenbergia rotunda vs control in asymptomatic COVID-19 [Internet]. Bethesda (MD): ClinicalTrials.gov; 2021 [cited 2021 Dec 10]. <https://clinicaltrials.gov/ct2/show/NCT05019326>
Hu XY, Wu RH, Logue M, Blondel C, Lai LYW, Stuart B, et al. Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis. PLoS ONE. 2018 Nov 14;13(11):e0207713. doi: 10.1371/journal.pone.0207713.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
